JP2001272403A - Method for converting blood determination result - Google Patents
Method for converting blood determination resultInfo
- Publication number
- JP2001272403A JP2001272403A JP2000126669A JP2000126669A JP2001272403A JP 2001272403 A JP2001272403 A JP 2001272403A JP 2000126669 A JP2000126669 A JP 2000126669A JP 2000126669 A JP2000126669 A JP 2000126669A JP 2001272403 A JP2001272403 A JP 2001272403A
- Authority
- JP
- Japan
- Prior art keywords
- value
- whole blood
- measurement
- plasma
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 52
- 239000008280 blood Substances 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims description 25
- 238000005534 hematocrit Methods 0.000 claims abstract description 25
- 210000002966 serum Anatomy 0.000 claims abstract description 21
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 20
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 20
- 238000005259 measurement Methods 0.000 claims description 44
- 210000002381 plasma Anatomy 0.000 claims description 27
- 210000000601 blood cell Anatomy 0.000 claims description 6
- 230000001900 immune effect Effects 0.000 claims description 3
- 239000003219 hemolytic agent Substances 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 238000000926 separation method Methods 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 108700021935 methemoglobin azide Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- -1 potassium ferricyanide Chemical compound 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、血液中の特定成分の測
定において、全血状態で得られた測定結果から、血清又
は血漿を仮想的に測定した場合の測定値へ変換する方法
に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for converting a measurement result obtained in a whole blood state into a measurement value obtained by virtually measuring serum or plasma in measuring a specific component in blood.
【０００２】[0002]
【従来の技術】医療分野、医学研究分野などにおいて、
血液中の特定成分（肝炎ウイルス、リウマチ因子、Ｃ反
応性蛋白質等）を測定することが必要とされ、そのため
に種々の測定方法が開発され、実施されている。2. Description of the Related Art In the medical field and medical research field,
It is necessary to measure specific components (hepatitis virus, rheumatoid factor, C-reactive protein, etc.) in blood, and various measuring methods have been developed and implemented for that purpose.
【０００３】中でも一般的に採用されている方法は、患
者や被測定者から血液を採取し、得られた血液（以下、
全血という）を遠心分離し、上澄み（血清又は血漿）を
得、これを適当な緩衝液により希釈し、血清又は血漿中
の特定成分と反応する試薬と接触させることで、化学的
変化（色素や凝集による光学的・電気化学的等）を測定
するものである。[0003] Above all, a generally adopted method is to collect blood from a patient or a subject, and obtain the obtained blood (hereinafter, referred to as "blood").
The whole blood is centrifuged to obtain a supernatant (serum or plasma), which is diluted with an appropriate buffer and brought into contact with a reagent that reacts with a specific component in serum or plasma to undergo a chemical change (dye). And optical / electrochemical due to aggregation).
【０００４】これは、通常は血清又は血漿測定値として
表す項目を全血での測定に供すると、得られた全血測定
値は希望する血清又は血漿測定値とと大きく異なるとい
う問題が生じるためであり、全血を検体とした場合に多
量に含まれる血球成分が測定値へ干渉することが原因で
ある。[0004] This is because when an item which is usually expressed as a serum or plasma measurement value is subjected to measurement with whole blood, there arises a problem that the obtained whole blood measurement value is significantly different from a desired serum or plasma measurement value. This is because, when whole blood is used as a sample, a large amount of blood cell components interferes with the measured value.
【０００５】しかし、上記のような方法では遠心分離作
業を必要とし、一連の測定作業が煩雑になるだけでな
く、経験と熟練を必要とする。そのため、直接に全血を
測定し、その測定結果を用いて血清又は血漿を測定した
場合の測定値を求める手法が望まれている。[0005] However, the above-described method requires a centrifugal separation operation, which not only complicates a series of measurement operations but also requires experience and skill. Therefore, there is a demand for a method of directly measuring whole blood and using the measurement result to obtain a measurement value when measuring serum or plasma.
【０００６】そのような全血を直接に測定する手法とし
て、全血試料へ溶血剤を添加することで血球成分を破壊
し、ついで免疫学的測定方法等を施すことにより、遠心
分離をすること無しに、血清又は血漿中に含まれる測定
対象成分を直接に測定する方法がある（特開昭６０−４
７９６２号、特開昭６０−２４４８６１号、特開平９−
２７４０４１号等）。[0006] As a technique for directly measuring such whole blood, a blood cell component is destroyed by adding a hemolytic agent to a whole blood sample, and then centrifugation is performed by performing an immunological measurement method or the like. There is a method of directly measuring a component to be measured contained in serum or plasma without using the method (Japanese Patent Laid-Open No. Sho 60-4).
No. 7962, JP-A-60-244861, JP-A-9-
No. 270441).
【０００７】しかし、このような手法においても、血清
又は血漿を測定した場合の本来の測定値を求める際に
は、得られた全血測定値を数学的に補正・変換する必要
がある。However, even in such a method, it is necessary to mathematically correct and convert the obtained whole blood measurement value when obtaining the original measurement value when measuring serum or plasma.
【０００８】そのため特開平９−２７４０４１号では、
全血中の物質Ｘの濃度は血清中の物質Ｘの濃度よりも低
いとし、その誤差を変換するために、あらかじめ測定し
て求めたヘマトクリット値を用いる関係式を使用してい
る。ヘマトクリット値とは、血液の中に含まれる赤血球
の容積比率である。[0008] Therefore, in Japanese Patent Application Laid-Open No. 9-274401,
It is assumed that the concentration of substance X in whole blood is lower than the concentration of substance X in serum, and in order to convert the error, a relational expression using a hematocrit value measured and obtained in advance is used. The hematocrit value is a volume ratio of red blood cells contained in blood.
【０００９】しかしこの方法は、あらかじめヘマトクリ
ット値を別個に測定しておかなければならず、結局は遠
心分離作業や電気抵抗法等の電気的手段による煩雑なヘ
マトクリット値測定作業を一度は必要とする。However, in this method, the hematocrit value must be separately measured in advance, and after all, a complicated hematocrit value measurement operation by an electric means such as a centrifugal separation operation or an electric resistance method is once required. .
【００１０】[0010]
【発明が解決しようとする課題】そこで本発明の目的
は、このように煩雑なヘマトクリット値測定作業を予め
全く必要とせずに、全血状態で得られた血液測定結果か
ら、血清又は血漿を測定した場合の測定値へ容易に補正
・変換する方法を提供することである。Accordingly, an object of the present invention is to measure serum or plasma from blood measurement results obtained in a whole blood state without such a complicated hematocrit value measurement operation in advance. It is an object of the present invention to provide a method of easily correcting and converting the measured value into the measured value.
【００１１】[0011]
【課題を解決するための手段】上記課題を解決するため
に、本発明は、全血を測定対象物として得られた測定結
果から、血清又は血漿を測定した場合の測定値へ変換す
る測定において、全血中のヘモグロビン濃度（ｇ／ｄ
ｌ）を測定し、得られたヘモグロビン濃度を約３倍した
数値をヘマトクリット値（％）として採用し、そのヘマ
トクリット値を用いて、全血の測定結果から血清又は血
漿を測定した場合の測定値へ変換することを特徴とす
る、血液測定結果の変換方法である。Means for Solving the Problems In order to solve the above problems, the present invention relates to a measurement for converting a measurement result obtained from whole blood as a measurement target into a measurement value when measuring serum or plasma. , Hemoglobin concentration in whole blood (g / d
l) is measured, a value obtained by multiplying the obtained hemoglobin concentration by about 3 times is adopted as a hematocrit value (%), and a measurement value when serum or plasma is measured from a measurement result of whole blood using the hematocrit value This is a method for converting a blood measurement result, which is characterized by converting the blood measurement result into a blood measurement result.
【００１２】[0012]
【発明の実施の形態】「医学検査」４７巻３号５３３頁
（１９９８）において、第４７回日本臨床衛生検査学会
の一抄録として、血球算定（血算）データ中、赤血球・
ヘモグロビン濃度（単位：ｇ／ｄｌ） ・ヘマトクリッ
ト値間（単位：％）には三倍則が成立することが言及さ
れており、この三倍則の有効性に関しての考察が述べら
れている。BEST MODE FOR CARRYING OUT THE INVENTION In "Medical Examination" Vol. 47, No. 3, page 533 (1998), as an abstract of the 47th Japan Society for Clinical Health Examination, red blood cells
Hemoglobin concentration (unit: g / dl) It is mentioned that a triple law is established between hematocrit values (unit:%), and consideration is given regarding the effectiveness of the triple rule.
【００１３】本発明は、いわば、この三倍則の法則を、
全血を測定対象物として血清又は血漿を仮想的に測定す
る場合、特に、特開昭６０−４７９６２号をはじめとす
る血球成分を破壊して測定する場合に応用したものであ
る。このように非常に便利な三倍則の法則が、現在まで
実際の測定に応用されていなかったのは、盲点であり、
意外なことである。According to the present invention, the rule of this triple law is
The present invention is applied to a case where serum or plasma is virtually measured using whole blood as a measurement target, and in particular, a case where blood cell components are destroyed and measured as disclosed in JP-A-60-47962. It is a blind spot that such a very useful triple law has not been applied to actual measurements until now.
That is surprising.
【００１４】換言すれば、ヘマトクリット値を用いて全
血測定値から血漿又は血清測定値へ数学的に変換するこ
とは通常行われていることだが、本発明は、そのヘマト
クリット値自体を数学的に求めるのである。In other words, although it is common practice to use a hematocrit value to mathematically convert a whole blood measurement to a plasma or serum measurement, the present invention mathematically converts the hematocrit itself. Ask for it.
【００１５】得られたヘマトクリット値を用いて、全血
試料中の対象物濃度を血漿又は血清試料中の対象物濃度
へ変換する式は以下のとおりである。 血清又は血漿中濃度＝全血中濃度÷ヘマトクリット値
（％）×１００Using the obtained hematocrit value, a formula for converting the concentration of a target in a whole blood sample into the concentration of a target in a plasma or serum sample is as follows. Serum or plasma concentration = whole blood concentration / hematocrit value (%) x 100
【００１６】血球成分のうち、赤血球がそのほとんどを
占めるため、赤血球中成分のヘモグロビン濃度を測定す
るだけで、ほとんど誤差も無くヘマトクリット値に変換
できる。Since red blood cells occupy most of the blood cell components, it can be converted into a hematocrit value with almost no error only by measuring the hemoglobin concentration of the red blood cell components.
【００１７】ヘモグロビン濃度は、特定成分を測定する
と同時に測定する。ヘモグロビンの着色を利用して光学
的に測定しても良く、試薬を投入することで測定するこ
とも好ましい。いずれにせよ、ヘモグロビン濃度は非常
に簡易な測定方法が確立されており、いずれの方法を用
いても構わない。The hemoglobin concentration is measured simultaneously with the measurement of the specific component. The measurement may be performed optically using the coloring of hemoglobin, and it is also preferable to perform the measurement by adding a reagent. In any case, a very simple method for measuring the hemoglobin concentration has been established, and any method may be used.
【００１８】全血試料中の対象物濃度の測定は、故意に
血球を溶血させ、対象物に特有の抗体で直接的に測定す
るという、免疫学的手法で測定することが好ましい。た
だし、本発明における測定項目は、ヘモグロビンの影響
を直接的又は間接的に受けないものに限られることは言
うまでもない。The concentration of the target substance in the whole blood sample is preferably measured by an immunological technique in which blood cells are intentionally lysed and directly measured with an antibody specific to the target substance. However, it goes without saying that the measurement items in the present invention are limited to those that are not directly or indirectly affected by hemoglobin.
【００１９】[0019]
【実施例】（実施例１）まず、本発明者らは病院施設か
ら入手した合計１４，０００名分の血液測定データを得
て、ヘモグロビン濃度をアジドメトヘモグロビン法に基
づき測定し、ヘマトクリット値を電気抵抗法に基づく血
球計数装置のデータを用い、ヘモグロビン濃度（Ｘ軸）
とヘマトクリット値（Ｙ軸）との相関を取った。両者の
相関図を図１に示す。図１中のＡとＢは施設が異なる
が、得られた相関式からも両者は完全に比例関係にある
と言ってよい。EXAMPLES (Example 1) First, the present inventors obtained blood measurement data for a total of 14,000 persons obtained from hospital facilities, measured the hemoglobin concentration based on the azidomethemoglobin method, and determined the hematocrit value. Hemoglobin concentration (X-axis) using data from a hemocytometer based on the electrical resistance method
And hematocrit value (Y-axis). FIG. 1 shows a correlation diagram between the two. Although facilities A and B in FIG. 1 are different, it can be said that both are completely proportional to each other from the obtained correlation formula.
【００２０】そうして、上記の１４，０００名のデータ
より、下記の比例式を得た。係数は、検体の実測値から
導いた数値である。 （ヘマトクリット値％）＝２．９５×（ヘモグロビン濃
度ｇ／ｄｌ） このように、ヘモグロビン濃度（ｇ／ｄｌ）を３倍する
ことでヘマトクリット値（％）を算出できることが確認
された。Then, the following proportional expression was obtained from the data of 14,000 persons. The coefficient is a numerical value derived from the measured value of the sample. (Hematocrit value%) = 2.95 × (Hemoglobin concentration g / dl) Thus, it was confirmed that the hematocrit value (%) can be calculated by multiplying the hemoglobin concentration (g / dl) by three times.
【００２１】（実施例２）次に、溶血性連鎖球菌毒素
（ＡＳＯ）の免疫測定において、実際に本発明にかかわ
る変換換算方法を用いた実験を示す。無作為に抽出した
６０名分の全血検体を使用し、ＡＳＯを添加した際の、
血漿を測定対象とした本来の値と、全血を測定対象とし
本発明を用いた換算後の血漿値との自己相関試験を行っ
た。Example 2 Next, an experiment using the conversion conversion method according to the present invention in an immunoassay for hemolytic streptococcal toxin (ASO) will be described. Using a randomly extracted whole blood sample of 60 individuals, when ASO was added,
An autocorrelation test was performed between an original value for plasma as a measurement target and a converted plasma value using the present invention for whole blood as a measurement target.
【００２２】血漿成分は、全血試料を遠心分離すること
で得た。得られた血漿成分へ希釈液と緩衝液を添加し、
抗ＡＳＯ抗体を固相化したラテックス試薬を加えて混和
し、直ちに波長６５０〜６７０ｎｍにおける一定時間後
の濁度変化量を求めた。得られた濁度変化量からＡＳＯ
濃度を求めた。The plasma component was obtained by centrifuging a whole blood sample. A diluent and a buffer are added to the obtained plasma component,
A latex reagent on which an anti-ASO antibody was immobilized was added and mixed, and the turbidity change after a certain time at a wavelength of 650 to 670 nm was immediately determined. From the turbidity change amount obtained, ASO
The concentration was determined.
【００２３】全血試料に対するヘモグロビン濃度測定
は、通常のアジドメトヘモグロビン法に従って測定し
た。すなわち、フェリシアン化カリウムで処理してメト
ヘモグロビンとし、さらにアジ化ナトリウムで処理して
アジドメトヘモグロビンとし、波長５６５ｎｍでの吸光
度からヘモグロビン濃度（ｇ／ｄｌ）を算出した。The hemoglobin concentration of a whole blood sample was measured according to the usual azidomethemoglobin method. That is, it was treated with potassium ferricyanide to obtain methemoglobin, and further treated with sodium azide to obtain azidomethemoglobin, and the hemoglobin concentration (g / dl) was calculated from the absorbance at a wavelength of 565 nm.
【００２４】得られたヘモグロビン濃度（ｇ／ｄｌ）を
実施例１で得られた式に代入し、得られた数値をヘマト
クリット値（％）とした。The obtained hemoglobin concentration (g / dl) was substituted into the equation obtained in Example 1, and the obtained value was used as the hematocrit value (%).
【００２５】次に、先の全血試料と同じ試料を対象とし
て希釈液並びに緩衝液を混和し、抗ＡＳＯ抗体を固相化
したラテックス試薬を添加して直ちに波長６６０ｎｍに
おける５分後の濁度変化量を求めた。予め作成しておい
た検量線により、試料の濁度変化量から全血を対象とし
たＡＳＯ価を求めた。Next, the same sample as the whole blood sample was mixed with a diluent and a buffer, and a latex reagent on which an anti-ASO antibody was immobilized was added, followed immediately by turbidity after 5 minutes at a wavelength of 660 nm. The amount of change was determined. The ASO value for whole blood was determined from the turbidity change of the sample using a previously prepared calibration curve.
【００２６】そうして、全血を対象として得られたＡＳ
Ｏ値を、先に本発明により得られたヘマトクリット値を
用いて、血漿中のＡＳＯ値へと変換した。The AS obtained from whole blood
The O value was converted to an ASO value in plasma using the hematocrit value previously obtained according to the present invention.
【００２７】血漿を測定対象とした本来の値をＸ軸に、
全血を測定対象とし本発明を用いた換算後の血漿値をＹ
軸とし、相関図を図２に示す。図２から判るように、血
漿を実際に測定した値と、本発明を用いて求めたヘマト
クリット値から全血測定値を血漿測定値に換算した値と
は良好に相関し、両者は同等の威力を有する。On the X-axis, the original value for the measurement target of plasma is
Using whole blood as a measurement target, the converted plasma value using the present invention is represented by Y
The correlation diagram is shown in FIG. As can be seen from FIG. 2, the value obtained by actually measuring the blood plasma and the value obtained by converting the measured value of the whole blood from the hematocrit value obtained using the present invention to the measured value of the blood plasma are well correlated with each other. Having.
【００２８】[0028]
【発明の効果】以上、詳説したように、本発明を用いる
と、あらかじめヘマトクリット値を遠心分離作業といっ
た別の手段で特定しておく必要もなく、全血状態で得た
血液測定結果から、計算のみで血清又は血漿を測定した
場合の測定値へ補正・変換することができる。As described in detail above, according to the present invention, it is not necessary to specify the hematocrit value in advance by another means such as centrifugal separation, and the calculation is performed from the blood measurement result obtained in the whole blood state. It is possible to correct and convert to a measured value when serum or plasma is measured only by using.
【図１】 Ａ，Ｂとも、ヘモグロビン濃度−ヘマトクリ
ット値間の相関を示す相関図である。FIG. 1 is a correlation diagram showing the correlation between hemoglobin concentration and hematocrit value for both A and B.
【図２】 実際の血漿測定値と、全血を対象として本発
明を用いて求めた換算値との間の相関を示す相関図であ
る。FIG. 2 is a correlation diagram showing a correlation between actual measured plasma values and converted values obtained by using the present invention for whole blood.
Claims (2)
果から、血清又は血漿を測定した場合の測定値へ変換す
る測定において、 全血中のヘモグロビン濃度（ｇ／ｄｌ）を測定し、得ら
れたヘモグロビン濃度を約３倍した数値をヘマトクリッ
ト値（％）として採用し、そのヘマトクリット値を用い
て、全血の測定結果から血清又は血漿を測定した場合の
測定値へ変換することを特徴とする、血液測定結果の変
換方法。In a measurement for converting a measurement result obtained from whole blood as a measurement target into a measurement value when measuring serum or plasma, a hemoglobin concentration (g / dl) in whole blood is measured, A value obtained by multiplying the obtained hemoglobin concentration by about 3 times is adopted as a hematocrit value (%), and using the hematocrit value, the measurement result of whole blood is converted into a measurement value when serum or plasma is measured. The method of converting blood measurement results.
理することで血球成分を溶血させ、しかる後に特定成分
を免疫学的方法で直接に測定する、特許請求の範囲第１
項に記載の方法。2. The method according to claim 1, wherein, when measuring whole blood, the blood is treated with a hemolytic agent to lyse blood cell components, and then a specific component is directly measured by an immunological method.
The method described in the section.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000126669A JP2001272403A (en) | 2000-03-23 | 2000-03-23 | Method for converting blood determination result |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000126669A JP2001272403A (en) | 2000-03-23 | 2000-03-23 | Method for converting blood determination result |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001272403A true JP2001272403A (en) | 2001-10-05 |
Family
ID=18636406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000126669A Pending JP2001272403A (en) | 2000-03-23 | 2000-03-23 | Method for converting blood determination result |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001272403A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006510902A (en) * | 2002-12-20 | 2006-03-30 | オプトキュー アーベー | Method and apparatus for blood measurement |
| WO2011125877A1 (en) | 2010-03-31 | 2011-10-13 | 積水メディカル株式会社 | Measurement method using immunochromatography, test strip for immunochromatography, and measurement reagent kit for immunochromatography |
| JP2012088299A (en) * | 2010-09-24 | 2012-05-10 | Horiba Ltd | Complete immunoassay device and complete immunoassay method |
| WO2013147200A1 (en) * | 2012-03-29 | 2013-10-03 | 積水メディカル株式会社 | Method for measuring hematocrit value |
| US9778184B2 (en) | 2014-02-25 | 2017-10-03 | Konica Minolta, Inc. | Measurement method and measurement device |
| JP2019086450A (en) * | 2017-11-09 | 2019-06-06 | 国立大学法人弘前大学 | Whole blood albumin analyzer and whole blood albumin analysis method |
-
2000
- 2000-03-23 JP JP2000126669A patent/JP2001272403A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006510902A (en) * | 2002-12-20 | 2006-03-30 | オプトキュー アーベー | Method and apparatus for blood measurement |
| WO2011125877A1 (en) | 2010-03-31 | 2011-10-13 | 積水メディカル株式会社 | Measurement method using immunochromatography, test strip for immunochromatography, and measurement reagent kit for immunochromatography |
| JP2012088299A (en) * | 2010-09-24 | 2012-05-10 | Horiba Ltd | Complete immunoassay device and complete immunoassay method |
| WO2013147200A1 (en) * | 2012-03-29 | 2013-10-03 | 積水メディカル株式会社 | Method for measuring hematocrit value |
| JPWO2013147200A1 (en) * | 2012-03-29 | 2015-12-14 | 積水メディカル株式会社 | Method for measuring hematocrit value |
| US9778184B2 (en) | 2014-02-25 | 2017-10-03 | Konica Minolta, Inc. | Measurement method and measurement device |
| JP2019086450A (en) * | 2017-11-09 | 2019-06-06 | 国立大学法人弘前大学 | Whole blood albumin analyzer and whole blood albumin analysis method |
| JP7015521B2 (en) | 2017-11-09 | 2022-02-03 | 国立大学法人弘前大学 | Whole blood albumin analyzer and whole blood albumin analysis method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Inker et al. | Estimated glomerular filtration rate from a panel of filtration markers—hope for increased accuracy beyond measured glomerular filtration rate? | |
| Burnett et al. | Recommendations for measurement of and conventions for reporting sodium and potassium by ion-selective electrodes in undiluted serum, plasma or whole blood | |
| Karon et al. | Comparison of lactate values between point-of-care and central laboratory analyzers | |
| Steele et al. | Analytic bias of thyroid function tests: analysis of a College of American Pathologists fresh frozen serum pool by 3900 clinical laboratories | |
| JP3331251B2 (en) | Method for measuring hemoglobin adducts | |
| Marlar et al. | Effect on routine and special coagulation testing values of citrate anticoagulant adjustment in patients with high hematocrit values | |
| Heller et al. | A simplified assay for porphyrins in whole blood | |
| JPH0344555A (en) | Measuring method of concentration of glucose | |
| Shephard et al. | Assessment of the Nova StatSensor whole blood point-of-care creatinine analyzer for the measurement of kidney function in screening for chronic kidney disease | |
| Paiva et al. | Comparison between the HemoCue® and an automated counter for measuring hemoglobin | |
| JP2001272403A (en) | Method for converting blood determination result | |
| Greenway et al. | Point-of-care monitoring of oral anticoagulation therapy in children | |
| Merlini et al. | Standardizing plasma protein measurements worldwide: a challenging enterprise | |
| Fuentes-Arderiu et al. | Pre-metrological (pre-analytical) variation of some biochemical quantities | |
| Bachorik et al. | Accuracy and precision of analyses for total cholesterol as measured with the Reflotron cholesterol method. | |
| Srinivasan et al. | Lipoprotein cholesterol in the serum of children, as determined independently by two different methods. | |
| JP3814300B2 (en) | Method for analyzing a medical sample containing hemoglobin | |
| Wang et al. | Verification of a novel point-of-care HbA1c device in real world clinical practice by comparison to three high performance liquid chromatography instruments | |
| Viljoen et al. | Analytical quality goals for parathyroid hormone based on biological variation | |
| Meex et al. | Analytical validation of the new plasma calibrated Accu-Chek® test strips (Roche Diagnostics) | |
| EP3457136A1 (en) | Method for calculating ratio of measurement object substance to comparison object substance, program, storage medium, and device | |
| Peet et al. | Near-patient testing of blood glucose using the Bayer Rapidlab 860 analyser in a regional neonatal unit | |
| Pant et al. | Blood glucose concentration measured in EDTA/F plasma and serum in a referral clinical laboratory in Nepal | |
| Wians Jr et al. | Evaluation of a direct spectrophotometric procedure for quantitating plasma hemoglobin | |
| Schaar et al. | Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia |